The FDA’s decision not to approve Lykos Therapeutics’ application for MDMA therapy for PTSD was not surprising given the advisory panel’s vote. Despite this, there is potential for psychedelics in healthcare, as seen in the progress of reproductive health. The approval of emergency contraception and mifepristone involved overcoming political hurdles and ensuring safety and effectiveness. Similarly, psychedelic medicine faces legal and policy challenges but has strong public support. Research demonstrating safety and effectiveness is crucial. Ongoing efforts to improve access and eliminate barriers are essential, mirroring the journey of reproductive health care. Embracing science and reducing stigma can lead to broader acceptance of psychedelic medicine.
Source link
Psychedelic medicine’s ‘Plan B’: Lessons from reproductive health
